Company Xtacy Therapeutics Corp. Deutsche Boerse AG
Equities
TT5
CA98423G1072
Investment Management & Fund Operators
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.011 EUR | 0.00% | -43.59% | -12.00% |
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Meris Kott
CEO | Chief Executive Officer | - | 30/17/30 |
Lindsey R. Perry
DFI | Director of Finance/CFO | 70 | 10/19/10 |
Monita Faris
SEC | Corporate Secretary | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Lindsey R. Perry
DFI | Director of Finance/CFO | 70 | 10/19/10 |
Meris Kott
CEO | Chief Executive Officer | - | 30/17/30 |
Ashleigh Vogstad
BRD | Director/Board Member | - | 30/19/30 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 54,576,471 | 48,683,850 ( 89.20 %) | 0 | 89.20 % |
Company contact information
Xtacy Therapeutics Corp.
1111 Melville Street Suite 100
V6E 3V6, Vancouver
+604-484-0355
http://globalwellnessstrategies.comSector
1st Jan change | Capi. | |
---|---|---|
+3.26% | 95.3B | |
+13.75% | 69.05B | |
+20.25% | 63.76B | |
+12.28% | 43.7B | |
+14.14% | 43.06B | |
+17.76% | 34.41B | |
+3.63% | 24.92B | |
-1.14% | 23.07B | |
+6.72% | 19.68B |
- Stock Market
- Equities
- XTCY Stock
- TT5 Stock
- Company Xtacy Therapeutics Corp.